ReviewPharmaceutical research1995
Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.
Review in Pharmaceutical research, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems.Medical oncology (Northwood, London, England) · 2025Review
- Rapid Detection ofACS omega · 2021Article
- Recent Advances in the Development of Bio-Reducible Polymers for Efficient Cancer Gene Delivery Systems.Cancer medicine journal · 2019Article
- Recent advances in the development of gene delivery systems.Biomaterials research · 2019Review
- Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.Chemistry & biology · 2015Article
- A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides.PloS one · 2015Article
- Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting.BioMed research international · 2014Article
- Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV.Infectious diseases in obstetrics and gynecology · 2014Review
- Versatile synthesis of amino acid functionalized nucleosides via a domino carboxamidation reaction.Beilstein journal of organic chemistry · 2014Article
- Diseases originate and terminate by genes: unraveling nonviral gene delivery.Drug delivery and translational research · 2013Article
- Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- DNA as therapeutics; an update.Indian journal of pharmaceutical sciences · 2009Article
- Delivery systems for in vivo use of nucleic Acid drugs.Drug target insights · 2007Article
- The role of high-resolution imaging in the evaluation of nanosystems for bioactive encapsulation and targeted nanotherapy.Micron (Oxford, England : 1993) · 2007Review
- RiboaptDB: a comprehensive database of ribozymes and aptamers.BMC bioinformatics · 2006Article
- 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing.Nucleic acids research · 2006Article
- DNA-based therapeutics and DNA delivery systems: a comprehensive review.The AAPS journal · 2005Review
- Condensation of oligonucleotides assembled into nicked and gapped duplexes: potential structures for oligonucleotide delivery.Nucleic acids research · 2005Article
- Innovations in oligonucleotide drug delivery.Journal of pharmaceutical sciences · 2003Review
- A fiber optic biosensor for fluorimetric detection of triple-helical DNA.Nucleic acids research · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nucleic acids are increasingly being considered for therapeutic uses, either to interfere with the function of specific nucleic acids or to bind specific proteins. Three types of nucleic acid drugs are discussed in this review: aptamers, compounds which bind specific proteins; triplex forming (antigene) compounds; which bind double stranded DNA; and ribozymes (catalytic RNA), which bind and cleave RNA targets. The binding of aptamers to protein may involve specific sequence recognition, although this is not always the case. The interaction of triplex forming oligonucleotides or ribozymes with their targets always involves specific sequence recognition and hybridization. Early optimism concerning the possibility of designing drugs without a priori knowledge of the structure of the target (except a nucleotide sequence) has been tempered by the finding that target structure has a dramatic effect upon the hybridization potential of the nucleic acid drug. Other obstacles to the creation of effective nucleic acid drugs are their relative high molecular weight (> 3300) and their sensitivity to degradation. The molecular weight of these compounds has created a significant delivery problem which needs to be solved if nucleic acid drugs are to become effective therapies.
Indexed as
Identifiers
7596980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.